Print

HVTN 120

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59?-or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Trial Details:

I/II Ongoing
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, GlaxoSmithKline June 01, 2017
ALVAC-HIV (vCP2438),gp120 96ZM651 gp120 (clade C strain) linked to transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain); protein clade C TV1.C gp120 Env and clade C 1086.C gp120 Env with MF59 OR AS01
ALVAC-HIV (vCP2438) Viral Vector - Pox
gp120 Protein
MF59
South Africa, Tanzania, Zambia 320
NCT03122223
https://clinicaltrials.gov/ct2/show/NCT03122223